PTSM: Pharmaceutical Technology Sourcing and Management
The company announced that it will be expanding its portfolio of single-use vessels for fermentation.
On July 5, 2016, Eppendorf announced that it would be expanding its portfolio of rigid-wall single-use vessels for fermentation. According to the company, the Eppendorf BioBLU 3f was developed specifically for microbial bioprocessing in working volumes of 1.25 to 3.75 L, extending the full range of operation for single-use fermentation from 60 mL to 3.75 L.
Eppendorf BioBLU f Single-Use Vessels specifically address the demands of high cell density fermentation of bacteria, yeasts, and fungi. Magnetic overhead drives featuring impellers support agitation rates up to 1200 rpm and provide high-performance mass transfer. The integrated cooling baffles enable efficient heat removal for exothermic processes and the rigid-wall industrial stirred-tank design ensures scalability and simplifies technology transfer.
Source: Eppendorf
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.